LATEST
Janel agreed to acquire EnCor BiotechnologynewNightfood Holdings acquired Jun Long Machine IndustrialnewClimb Global Solutions acquired NeoVADnewValor Energy agreed to acquire Glorious StarOakley Capital / Global Loan Agency ServicesTA Associates / MedEnvision: majority stakeLSEG agreed to acquire OctusStord / AMS Fulfillment: investmentCencora agreed to acquire American Oncology NetworkAPEX / KoraiSmith & Wesson Brands agreed to acquire Long Range IntermediateBose acquired Skullcandy
Open App
Agreement signedPublished 3 Oct 2022

Alexion, AstraZeneca Rare Disease /
LogicBio Therapeutics, Inc.

Alexion to Acquire LogicBio Therapeutics in Genomic Medicine Deal

Price per share
$2.07/share
Stage
Agreement signed
Source · 3 Oct 2022
See the source
01 / BuyerAlexion, AstraZeneca Rare Disease
02 / TargetLogicBio Therapeutics, Inc.
01

What happened

Alexion, AstraZeneca Rare Disease entered a definitive agreement to acquire LogicBio Therapeutics, Inc. The agreement calls for a cash tender offer for all outstanding shares at $2.07 per share.

LogicBio Therapeutics is a clinical-stage genetic medicine company focused on genome editing and gene delivery platforms for rare and serious diseases.

02

The source

Everything on this page comes from the source below.

01
Source · Source

Alexion to Acquire LogicBio Therapeutics in Genomic Medicine Deal

This document is the source for the companies, stage, figure and people on this page.

Original filingUnlock with Pro
03

Timeline

Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.

  1. Published by the source

    The source this page is built from.

The same firms, in other deals

The firms' deal history and connections across other deals.

These firms' full profiles are part of Pro.

Request accessAlready invited? Sign in

Carrywatch Pro is by invitation. An invite lets you buy Pro.